IMU's HER-Vaxx drug reduces risk of death by advanced metastatic gastric cancer of 58.2% in clinical trial

I am initiating this Thread because I believe that too many have forgotten the significance of this result.

IMU's HER-Vaxx drug reduces risk of death by advanced metastatic gastric cancer of 58.2% in clinical trial

ASX Announcement Sydney, Australia, 23 November 2020:

Imugene’s HER-Vaxx shows positive Overall Survival with Hazard Ratio of 0.418
in Ongoing Randomized Phase 2 Trial in Advanced Gastric Cancer.
__________________________________________________________________________

• Interim analysis in the randomized Phase 2 showed statistically significant overall survival
Hazard Ratio (HR) of 0.418 (80% 2-sided CI: 0.186, 0.942); HER-Vaxx showed a reduced
risk of death of 58.2% in the HER-Vaxx plus chemotherapy group as compared to
chemotherapy alone.
• The median overall survival (OS) for patients receiving HER-Vaxx plus chemotherapy was
14.2 months, compared to 8.8 months in patients treated with chemotherapy alone.
• The Phase 2 data represent a clinical proof-of-concept signal for HER-Vaxx when added to
chemotherapy and indicate that B-cell activating immunotherapy vaccines can induce
clinically active antibody responses.
• The Independent Data Monitoring Committee (IDMC) confirms a favourable survival
outcome with no added toxicity for HER-Vaxx combined with SOC chemotherapy over
chemotherapy alone and advises to lower the number of patients required for study
completion.